Boehringer, Last Humira Biosimilar Challenger, Settles With AbbVie

Boehringer Ingelheim on Tuesday (May 14) settled the last major outstanding patent lawsuit by aspiring biosimilar competitors against AbbVie’s blockbuster arthritis drug Humira. Lawmakers have scrutinized AbbVie for having 136 patents for Humira, and two Senate Judiciary Committee members introduced a bill to give the Federal Trade Commission more authority to sue over so-called “patent thickets.” Boehringer will be allowed to market its biosimilar, Cyltezo, on July 1, 2023, the same year several other competitors will be allowed to market...